Drug General Information (ID: DDIVY3B5FW)
Drug Name			Urokinase		Drug Info		Aminocaproic acid		Drug Info
Drug Type		Protein/peptide				Small molecule
Therapeutic Class		Thrombolytics				Antifibrinolytic Agents

Mechanism of Urokinase-Aminocaproic acid Interaction (Severity Level: Moderate)
Antagonize the effect of antithrombotic agents Click to Show/Hide Mechanism Graph
Drug Name		Urokinase				Aminocaproic acid
Mechanism		Thrombolytic agent				Thrombogenic effects
Key Mechanism Factor 1
		Factor Name		Antithrombotic agents
		Factor Description		The beneficial effects of antithrombotic agents are reduced, leading to an increased risk of thromboembolism, stroke and/or myocardial infarction.
Mechanism Description		Antagonize the effect of Urokinase when combined with Aminocaproic acid

Recommended Action
Management		No specific intervention is warranted, but clinicians should be alert to the potential for diminished therapeutic efficacy if a tissue plasminogen activator is administered to a patient who has been treated with an antifibrinolytic agent, and vice versa.

References
1	Product Information. LYSTEDA (tranexamic acid). Xanodyne Pharmaceuticals Inc, Newport, KY.
2	Product Information. Cyklokapron (tranexamic acid). Pharmacia and Upjohn, Kalamazoo, MI.
3	Product Information. Trasylol (aprotinin). Bayer, West Haven, CT.